Summary:
In adults with obesity participating in a double-blind clinical pharmacology study, once-daily oral semaglutide (dose-escalated to 50 mg over 20 weeks) significantly reduced energy intake by 39.2%, decreased body weight by 9.8%, and improved appetite control compared to placebo administered over the same 20-week period, though it was associated with no significant effect on gastric emptying.
| PICO | Description |
|---|---|
| Population | Adults with obesity (n=61) who participated in a clinical pharmacology, double-blind study. |
| Intervention | Once-daily oral semaglutide (dose-escalated to 50 mg over 20 weeks). |
| Comparison | Placebo treatment administered for the same 20-week period. |
| Outcome | Semaglutide significantly reduced energy intake by -39.2% compared to placebo (-59.0%, -19.4%), reduced body weight by 9.8% (placebo: 1.5%), decreased hunger, and increased fullness, satiety, and control of eating. No significant impact on gastric emptying was observed. |
Source: Blundell, John, et al. “Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.” Diabetes, Obesity and Metabolism. Read article here.
